Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (3): 58-62.doi: 10.6040/j.issn.1671-7554.0.2018.1411
LIU Ping, ZHUANG Xianghua, XU Min, ZHANG Liang, WANG Xuemeng, SHANG Pan, ZHENG Fengjie, CHEN Shihong
CLC Number:
| [1] 温旭东, 汤玮, 刘志民. 胰高血糖素样肽-1缓解糖尿病周围神经病变的机制研究进展[J].第二军医大学学报, 2011, 32(3):329-333. WEN Xudong, TANG Wei, LIU Zhimin. Glucagon-like peptide-1 alleviating peripheral neuropathy in diabetic patients:advance in mechanism[J]. Academic Journal of Second Military medical University, 2011, 32(3):329-333. [2] Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998, 15(7):539-553. [3] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1):4-67. [4] 陆游, 陆颖理. 糖尿病性周围神经病变发生机制的研究进展[J]. 上海交通大学学报(医学版), 2017, 37(10):1441-1445. LU You, LU Yingli. Progress in pathogenesis of diabetic peripheral neuropathy[J]. Journal of Shanghai Jiaotong University(Medical Science), 2017, 37(10):1441-1445. [5] Javed S, Alam U, Malik RA. Treating diabetic neuropathy:present strategies and emerging solutions[J]. Rev Diabet Stud, 2015, 12(1/2):63-83. [6] Malik RA. Why are there no good treatments for diabetic neuropathy?[J]. Lancet Diabetes Endocrinol, 2014, 2(8):607-609. [7] Winkler G. Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism[J]. Orv Hetil, 2013, 154(7):248-255. [8] Shen T, Xu BL, Lei T, et al. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway[J]. Exp Ther Med, 2018, 16(4):3121-3128. [9] Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metab, 2018, 27(4):740-756. [10] Cai XL, Gao XY, Yang WJ, et al. DPP-4 inhibitor treatment in Chinese type 2 diabetes patients: a meta-analysis[J]. Diabetes Technol Ther, 2016, 18(12):784-793. [11] Hölscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimers disease[J]. Alzheimers Dement, 2014, 10(1 Suppl):S47-S54. [12] Tai JJ, Liu WZ, Li YW, et al. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimers disease[J]. Brain Res, 2018, 1678:64-74. doi:10.1016/j.brainres.2017.10.012. [13] Hölscher C. The role of GLP-1 in neuronal activity and neurodegeneration[J]. Vitam Horm, 2010, 84:331-354. doi:10.1016/B978-0-12-381517-0.00013-8. [14] Feng P, Zhang XJ, Li DF, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinsons disease[J]. Neuropharmacology, 2018, 133:385-394. doi:10.1016/j.neuropharm.2018.02.012. [15] Cai XS, Tan ZG, Li JJ, et al. Glucagon-like peptide-1(GLP-1)treatment ameliorates cognitive impairment by attenuating arc expression in type 2 diabetic rats[J]. Med Sci Monit, 2017, 23:4334-4342. doi:10.12659/MSM.903252. [16] Liu WJ, Jin HY, Lee KA, et al. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats[J]. Br J Pharmacol, 2011, 164(5):1410-1420. [17] Ma JJ, Shi M, Zhang XC, et al. GLP-1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NF-κB signaling pathways in streptozotocin-induced diabetic rats[J]. Int J Mol Med, 2018, 41(5):2977-2985. [18] Yang CP, Li CI, Liu CS, et al. Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM[J]. Neurology, 2017, 88(10):944-951. [19] Selvarajah D, Wilkinson ID, Maxwell M, et al. Magnetic resonance neuroimaging study of brain structural differences in diabetic peripheral neuropathy[J]. Diabetes Care, 2014, 37(6):1681-1688. [20] Rizzo MR, Barbieri M, Marfella R, et al. Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082[J]. Diabetes Care, 2013, 36(1):e13. doi:10.2337/dc12-1436. [21] 赵亚丽. 2型糖尿病使用西格列汀对氧化应激和炎性反应状态的控制及对周围神经病变的影响[J]. 河北医药, 2017, 39(23):3550-3553. ZHAO Yali. Effects of sitagliptin on oxidative stress, inflammatory reactions and peripheral neuropathy of patients with type 2 diabetes mellitus[J]. Hebei Medical Journal, 2017, 39(23):3550-3553. [22] Heppner KM, Kirigiti M, Secher A, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate(Macaca mulatta)brain[J]. Endocrinology, 2015, 156(1):255-267. [23] 程茅薇, 顾萍, 马健, 等. 西格列汀对db/db糖尿病小鼠坐骨神经传导速度的影响[J]. 中国全科医学, 2011, 14(18):2055-2058. CHENG Maowei, GU Ping, MA Jian, et al. Effects of sitagliptin on motor nerve conduction velocity of sciatic nerve in db/db mice[J]. Chinese General Practice, 2011, 14(18):2055-2058. [24] Gong N, Xiao Q, Zhu B, et al. Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity[J]. J Neurosci, 2014, 34(15):5322-5334. [25] Tani S, Ken NG, Hirayama A. Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study[J]. Am J Cardiovasc Drugs, 2013, 13(6):443-450. [26] Yoon SA, Han BG, Kim SG, et al. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study(the GUARD Study)[J]. Diabetes Obes Metab, 2017, 19(4):590-598. [27] Marques C, Mega C, Gonçalves A, et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals[J]. Mediators Inflamm, 2014:538737. doi:10.1155/2014/538737. |
| [1] | LYU Li, JIANG Lu, CHEN Shihong, ZHUANG Xianghua, SONG Yuwen, WANG Dianhui, AN Wenjuan, LI Qian, PAN Zhe. Related factors of osteoporosis in 210 postmenopausal women with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 19-25. |
| [2] | Ping LIU,Yuwen SONG,Ping WANG,Guangwei TIAN,Fengjie ZHENG,Li LYU,Jiaojiao DU,Jing ZHANG,Xianghua ZHUANG,Shihong CHEN. Correlation between vitamin D deficiency and depression in patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 51-56,102. |
| [3] | GONG Luwei, ZHOU Lizhen, SU Guohai. Perindopril ameliorates cardiac dysfunction via Akt-FoxO1 pathway in diabetic cardiomyopathy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 65-70. |
| [4] | ZHAO Huichen, CHAI Jiachao, ZHANG Liang, YUAN Mingzhen, PENG Li, LIU Yuantao. Changes of hydrogen sulfide concentrations and synthetase expressions in the corpus cavernosum of diabetic rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(10): 25-28. |
| [5] | CHEN Zhixin, WANG Ying, CAO Xinran, HEI Naihao, LI Junlong, DONG Bo, GUAN Guangju. Evaluation of the protective effect of AVE0991 on streptozotocin-induced diabetic nephropathy rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(10): 29-33. |
| [6] | SHI Rui, SUN Pei, WANG Lulu, DING Lin, XIA Jin, WANG Yan, PANG Shuguang. Vitamin D and mecobalamin combined with mouse nerve growth factor for diabetic peripheral neuropathy: a clinical observation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(4): 64-67. |
| [7] | BI Da-peng1, JI Gao-de1, ZHAO Hong-xing2. Effects of Tongxinluo capsules on cystatin C in the early diabetic nephropathy patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(7): 67-69. |
| [8] |
ZHOU Yan1, GUO Li-xin1, ZHOU Lu2, WANG Yao1, MOU Zhong-qing1, WANG Xiao-xia1, YU Dong-ni1， ZHANG Li-na1.
Factors influencing diabetic peripheral neuropathy in elderly type 2 diabetic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(6): 1-4. |
| [9] | WANG Qian1, ZHANG Ying1, HOU Wei-Kai1, ZHANG Li2, XU Hua3, WANG Peng4， YU Shan1, LIU Qian1, HUANG Qing-Xian1. Correlation between type 2 diabetes associated diarrhea and changes of enteric nervous system [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(8): 13-. |
| [10] | KONG De-huan1, YU Jin-tang2, GAO Mei-juan1, LI Bo1, BIAN Li-xiang1, LI Ming-long3, LIU Ming4, YU Gui-na1. Protection of calcium dobesilate on the aorta of diabetic rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(10): 4-. |
| [11] | HOU Liang, LIU Xueping, YUAN Shuhua, WANG Meixia, XU Song. Level and injury mechanism of AGEs in the vascular system of insulin resistance rats and protective effects of Pioglitazone [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(4): 5-9. |
| [12] | ZHANG Yuehua, ZHAO Xinguo, YUE Yuguo, L Yingjun. Effects of Aspart 30 for new type 2 diabetes [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(4): 160-. |
| [13] | LI Qian, WANG Yi, SUN Shuzhen, CHEN Yao, WANG Lijun. Changes of collagen metabolism and MMP-2/TIMP-2 in hearts of diabetic rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(3): 1-6. |
| [14] | LI Wenbin1, CUI Meiyu1, XU Dongmei1,GUAN Guangju2. Correlation of dipeptidylpeptidase IV enzyme activity with diabetic nephropathy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(3): 12-14. |
| [15] | . Cardial protective effect of calcium dobesilate on diabetic rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(10): 9-14. |
|
||
